SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending as investors heavily scrutinize upcoming earnings, with active community debate over the companys massive cash position and the lack of a clear acquisition strategy. Market participants are divided between bullish sentiment regarding fundamental improvements and frustration over the stock's stagnant price action and recent leadership communication.

Far below the surface, where light no longer reaches and noise collapses into silence, the Sperm Whale endures.  It does not rely on speed or spectacle. It survives through mass, intelligence, and absolute awareness of its surroundings.  This project is shaped by the same principle — strength formed under pressure, movement guided by understanding, and conviction built where others cannot remain.  While the surface reacts, the deep decides.

The Sperm Whale

SPERMWHALE is experiencing intense volatility and speculative fervor as traders debate whether it is a legitimate breakout or a classic pump-and-dump scheme. The community is sharply divided, with some investors celebrating massive percentage gains while others warn of the risks associated with high concentration among top holders and the lack of fundamental utility.

FuboTV, Inc. is a consumer-first live TV streaming company with the mission of delivering premium sports, news and entertainment programming that offers greater choice, flexibility and value. The company was founded by David Gandler, Alberto Horihuela Suarez, and Sung Ho Choi on February 20, 2009 and is headquartered in New York, NY.

fuboTV Inc - Ordinary Shares - Class A

fuboTV Inc

FuboTV is facing intense community skepticism and selling pressure as investors grapple with an impending reverse stock split and a lack of clear guidance from management. Discussions are dominated by frustration over the company's declining share price and concerns regarding its long-term viability, with many participants debating whether to hold for a potential turnaround or exit to mitigate further losses.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is currently a focal point for investors following a significant NASA contract award, with the community actively debating how this reinforces the company's competitive position for future lunar mobility projects. While some traders are focused on short-term volatility and option activity, others are analyzing the company's broader role in long-term lunar infrastructure as it shifts focus toward upcoming program milestones.

iShares Trust - iShares Russell 2000 ETF

iShares Russell 2000 ETF

IWM is currently a focal point for the market as investors debate the impact of broader economic uncertainty, with community members actively monitoring the ETF for signs of a potential bottom or further downside following recent volatility. Discussions are heavily centered on whether small caps can maintain resilience or if they remain vulnerable to the intersection of persistent inflation, elevated energy costs, and the evolving geopolitical landscape.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood stock is facing intense downward pressure despite the announcement of a 1.5 billion dollar share repurchase program, with retail investors expressing deep frustration over the disconnect between the company's growth metrics and its recent market performance. The community is heavily focused on broader macro headwinds, including geopolitical tensions and crypto market volatility, while debating whether the current price levels represent a generational buying opportunity or an ongoing downtrend.

Circle Internet Group, Inc. is a financial technology company that enables businesses of all sizes to harness the power of digital currencies and public blockchains for payments, commerce and financial applications worldwide. The company was founded by Jeremy J. Allaire and Patrick Sean Neville in August 2013 and is headquartered in New York, NY.

Circle Internet Group Inc. - Ordinary Shares - Class A

Circle

Circle is experiencing extreme volatility as investors debate the impact of newly proposed legislation that would restrict passive yield generation on stablecoins. While the community is split between bullish sentiment driven by institutional adoption and bearish fears regarding the stock's parabolic run and long-term earnings model, heavy option volume and aggressive institutional flows have kept trading activity elevated.

Draganfly, Inc. engages in the manufacture and sale of commercial unmanned aerial vehicle systems and software serving the public safety, agriculture, industrial inspections, security, mapping, and surveying markets. Its products include quad-copters, fixed wing aircrafts, ground based robots, hand held controllers, and software used for tracking, live streaming, and data collection. The firm also offers custom engineering, training, simulation consulting, as well as data and flight training services. The company was founded by Zenon Dragan and Christine Dragan in 1998 and is headquartered in Saskatoon, Canada.

Draganfly Inc

Draganfly is seeing heightened investor attention as community members debate the impact of potential military contract opportunities and broader defense sector trends on the stock's valuation. While some traders express frustration with recent price volatility and past share offerings, others remain bullish on the long-term potential of the company's drone solutions, particularly as geopolitical tensions continue to drive demand for autonomous technology.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BCRX is experiencing a surge in trading volume and bullish sentiment driven by unconfirmed market rumors regarding potential M&A activity from a large-cap pharmaceutical suitor. The community is actively debating the credibility of these buyout whispers, with many long-term shareholders highlighting the company's strong commercial HAE franchise and pipeline as fundamental drivers for long-term value regardless of an exit.

BioLLM

BIOLLM is generating buzz as investors link the asset to broader momentum in artificial intelligence and the Solana ecosystem. Community discussions focus on strategic accumulation and potential integration with leading hardware and infrastructure partners.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Adial Pharmaceuticals Lead Drug Fits New Policy Mood As Bipartisan Bill Signals Broader Lens On Alcohol Use Disorder

Adial backs H.R. 7091 targeting AUD in veterans, spotlighting harm reduction therapies and expanding research beyond abstinence-based care.read more...

<ul class="summary-bullets"><li>The company announced a 1-for-25 reverse stock split.</li><li>The split takes effect Thursday, with split-adjusted trading Friday, reducing outstanding shares to about 1.1 million from 27.8 million.</li><li>The move comes amid continued progress on AD04, with Phase 3 planning completed.</li></ul>Shares of Adial Pharmaceuticals Inc.&nbsp;cratered over 20% in after-hours trading on Tuesday after the company announced a 1-for-25 reverse stock split to restore compliance with Nasdaq’s minimum bid price requirement.<h2 class="st-heading-2">ADIL Reverse Stock Split&nbsp;</h2>Adial said the reverse split will take effect Thursday, with the stock set to begin trading on a split-adjusted basis on Friday. This will reduce outstanding common shares to nearly 1.1 million from about 27.8 million, while shareholder ownership percentages will remain unchanged, apart from the treatment of fractional shares. The company added that proportional adjustments will be made to outstanding equity awards and warrants, including exercise prices.Adial said the reverse split is intended to bring the company back into compliance with Nasdaq’s $1 minimum bid price rule, a requirement for maintaining its listing.<h2 class="st-heading-2">AD04 Development In Focus</h2>The reverse split comes as Adial continues to advance AD04, its genetically targeted serotonin-3 receptor antagonist for the treatment of Alcohol Use Disorder, with a focus on heavy drinking patients and select genotypes.The company has advanced Phase 3 trial design and planning, drawing on analyses of historical clinical data that identified genotype-defined subgroups more likely to benefit from the therapy.&nbsp;On the regulatory front, Adial completed its End-of-Phase-2 discussions with the U.S. Food and Drug Administration (FDA), saying the agency provided input on the Phase 3 adaptive trial design and the broader clinical program. The company said the discussions covered key elements such as patient population, endpoints, dosing, and confirmation of biomarker-positive and biomarker-negative groups, including a focus on the AG+ genotype, and were later formalized through final FDA meeting minutes.Adial has also worked to strengthen intellectual property protection for AD04, saying an international patent application covering the program has been published and, if granted, is expected to protect its core assets through at least 2045.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment was ‘bearish’ amid ‘normal’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/adil_ss_png_001d17e3e8.webp" alt="adil ss.png" width="975" height="148"><figcaption>ADIL sentiment and message volume as of February 3 | Source: Stocktwits</figcaption></figure>One user said the market reaction appeared overly short-term focused, adding that near-term share price moves mattered less to them, as they viewed Adial as a “long-term story” and said the company’s underlying clinical progress has been moving well.<stembedurl>https://stocktwits.com/Prazzclatt/message/643712705</stembedurl>Another user said, “more dilution will follow after min price bid met. It will be voted on at end of the month. This will likely be below $1 again by March.”<stembedurl>https://stocktwits.com/StayPresent/message/643885507</stembedurl><a href="https://stocktwits.com/symbol/ADIL">ADIL’s stock</a> has declined 75% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

ADIL’s stock has declined 75% over the past 12 months.

Why Did Adial Pharmaceuticals Stock Plunge Over 20% After Hours Today?

The reverse split is intended to bring the company back into compliance with Nasdaq’s $1 minimum bid price rule.

Equity

Has Acurx Pharmaceuticals (ACXP) Outpaced Other Medical Stocks This Year?

Here is how Acurx Pharmaceuticals, Inc. (ACXP) and Adial Pharmaceuticals, Inc. (ADIL) have performed compared to their sector so far this year.

All You Need to Know About Adial Pharmaceuticals (ADIL) Rating Upgrade to Buy

Adial Pharmaceuticals (ADIL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Adial Pharmaceuticals (ADIL) Upgraded to Strong Buy: Here's Why

Adial Pharmaceuticals (ADIL) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Retail investors are buzzing about Adial Pharmaceuticals after the company announced the issuance of a key U.S. patent, which strengthens its strategy in precision medicine for addiction treatment.&nbsp;The announcement sent shares soaring to $0.78 during Thursday’s session — the stock’s highest level since February.The patent, officially granted on April 15 by the United States Patent and Trademark Office (USPTO), covers a novel method of treating alcohol- and opioid-related disorders using Adial’s investigational therapy, AD04, in patients with specific genetic markers.The company’s approach positions AD04 as a targeted therapy — not a one-size-fits-all solution — marking a significant step forward in the personalized treatment of addiction.The newly issued patent outlines the administration of AD04 to individuals with serotonin-related gene variations, including genotypes of HTR3A, HTR3B, and SLC6A4, such as the LL genotype of 5-HTTLPR, along with SNPs rs1150226, rs17614942, and rs1176713.&nbsp;The claims also include dosing regimens customized to these genetic profiles — a key component of Adial’s precision medicine approach.In addition to alcohol use disorder (AUD), the patent extends to a wide range of related conditions, including alcohol-induced anxiety, bipolar disorder, sexual dysfunction, sleep disturbances, gambling disorder, and alcohol withdrawal.&nbsp;The retail trading community was quick to react on Stocktwits.&nbsp;Sentiment&nbsp;flipped to ‘extremely bullish’ amid ‘extremely high’ message volume, underscoring strong retail engagement.&nbsp;One user said, “Great news today sent it flying,” while another predicted the stock could jump 50% to 100% in after-hours or the following day, calling the initial 11% gain “a bargain.”<stembedurl>https://stocktwits.com/GracebyFaith/message/613308669</stembedurl><stembedurl>https://stocktwits.com/KING_CRUSH/message/613278365</stembedurl>That retail enthusiasm is complemented by positive analyst coverage. According to data from Koyfin, two of the three analysts covering Adial currently rate the stock a ‘Buy,’ with the third assigning a ‘Hold.’&nbsp;Notably, no analysts have issued ‘Sell’ or ‘Strong Sell’ ratings.Despite Thursday’s spike, Adial shares remain down 26.4% year-to-date, underperforming the broader market. In comparison, the Nasdaq is down 1.7%, while the Dow and S&amp;P 500 have declined 3.9% and 4.5%, respectively, over the same period.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Dirty needles are collected by outreach workers with St. Ann’s Corner of Harm Reduction as they participate in a weekly needle clean-up at a Bronx park that drug users often use on April 23, 2025 in New York City. (Photo by Spencer Platt/Getty Images)

Retail Traders Flock To Adial Pharma After Patent News Sends Shares Soaring

Adial Pharmaceuticals jumped to its highest level since February after receiving a U.S. patent for its precision medicine approach to treating addiction. The patent supports the use of AD04 in patients with specific genetic markers.

Adial Pharmaceuticals, Inc. engages in the development of therapeutics for the treatment or prevention of addiction and related disorders. It offers the AD04, a selective serotonin-3 antagonist. The company was founded by Bankole A. Johnson and William B. Stilley, III in November 2010 and is headquartered in Glen Allen, VA.

ADIL
Adial Pharmaceuticals Inc

Feed

News

Sentiment

Fundamentals

Info

Latest ADIL News

ADILAdial Pharmaceuticals Inc